Related references
Note: Only part of the references are listed.Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma
Leigh Ellis et al.
CLINICAL CANCER RESEARCH (2008)
To Die or Not to Die: That is the Autophagic Question
Maria Maiuri et al.
CURRENT MOLECULAR MEDICINE (2008)
Big wheel keeps on turning: apoptosome regulation and its role in chemoresistance
B. Fadeel et al.
CELL DEATH AND DIFFERENTIATION (2008)
The roles of therapy-induced autophagy and necrosis in cancer treatment
Ravi K. Amaravadi et al.
CLINICAL CANCER RESEARCH (2007)
Apaf-1 and caspase-9 deficiency prevents apoptosis in a Bax-controlled pathway and promotes clonogenic survival during paclitaxel treatment
Katja Janssen et al.
BLOOD (2007)
Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance
Jennifer S. Carew et al.
BLOOD (2007)
Functional and physical interaction between Bcl-XL and a BH3-like domain in Beclin-1
M. Chiara Maiuri et al.
EMBO JOURNAL (2007)
Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma
R. K. Lindemann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Histone deacetylase inhibitors in cancer therapy
Walid K. Rasheed et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2007)
Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma
Ravi K. Amaravadi et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Potential therapeutic applications of autophagy
David C. Rubinsztein et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Activation of mitochondrial pathway is crucial for tumor selective induction of apoptosis by LAQ824
Shaowen Wang et al.
CELL CYCLE (2006)
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies
Francis Giles et al.
CLINICAL CANCER RESEARCH (2006)
The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance
Patricia Maiso et al.
CANCER RESEARCH (2006)
The apoptosome: Physiological, developmental, and pathological modes of regulation
Zachary T. Schafer et al.
DEVELOPMENTAL CELL (2006)
Apaf-1 and caspase-9 are required for cytokine withdrawal-induced apoptosis of mast cells but dispensable for their functional and clonogenic death
VS Marsden et al.
BLOOD (2006)
Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?
SB Baylin et al.
NATURE REVIEWS CANCER (2006)
Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589
DZ Qian et al.
CLINICAL CANCER RESEARCH (2006)
被撤回的出版物: The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide (Retracted article. See vol. 95, pg. 336, 2019)
RR Rosato et al.
MOLECULAR PHARMACOLOGY (2006)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Lysosomes and autophagy in cell death control
G Kroemer et al.
NATURE REVIEWS CANCER (2005)
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90 - A novel basis for antileukemia activity of histone deacetylase inhibitors
P Bali et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Expression and function of the apoptosis effector Apaf-1 in melanoma
LTC Peltenburg et al.
CELL DEATH AND DIFFERENTIATION (2005)
Is Apaf-1 expression frequently abrogated in melanoma?
JD Allen et al.
CELL DEATH AND DIFFERENTIATION (2005)
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3
P George et al.
BLOOD (2005)
Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells
A Nebbioso et al.
NATURE MEDICINE (2005)
Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway
A Insinga et al.
NATURE MEDICINE (2005)
Ceramide-mediated macroautophagy involves inhibition of protein kinase B and up-regulation of beclin 1
F Scarlatti et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Cotreatment with histone deacetylase inhibitor LAQ824 enhances apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells
F Guo et al.
CANCER RESEARCH (2004)
Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824
P Atadja et al.
CANCER RESEARCH (2004)
Apaf-1 and caspase-9 do not act as tumor suppressors in myc-induced lymphomagenesis or mouse embryo fibroblast transformation
CL Scott et al.
JOURNAL OF CELL BIOLOGY (2004)
The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584
DZ Qian et al.
CANCER RESEARCH (2004)
Apoptotic and autophagic cell death induced by histone deacetylase inhibitors
YF Shao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo
E Weisberg et al.
LEUKEMIA (2004)
Methods for monitoring autophagy
N Mizushima
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2004)
Apaf-1 and caspase-9 accelerate apoptosis, but do not determine whether factor-deprived or drug-treated cells die
PG Ekert et al.
JOURNAL OF CELL BIOLOGY (2004)
Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease
B Ravikumar et al.
NATURE GENETICS (2004)
NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma
L Catley et al.
BLOOD (2003)
Role of caspases, bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) suberoylanilide hydroxamic acid and (SAHA)
C Henderson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome
VS Marsden et al.
NATURE (2002)
A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy
CA Schmitt et al.
CELL (2002)
Apoptosis: A link between cancer genetics and chemotherapy
RW Johnstone et al.
CELL (2002)
The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species
AA Ruefli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Defective cytochrome c-dependent caspase activation in ovarian cancer cell lines due to diminished or absent apoptotic protease activating factor-1 activity
BB Wolf et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Apaf-1 protein deficiency confers resistance to cytochrome c-dependent apoptosis in human leukemic cells
L Jia et al.
BLOOD (2001)
Inactivation of the apoptosis effector Apaf-1 in malignant melanoma
MS Soengas et al.
NATURE (2001)
Genetic analysis of chemoresistance in primary murine lymphomas
CA Schmitt et al.
NATURE MEDICINE (2000)
Share Paper
